(RTTNews) - Nyxoah S.A. (NYXH) has announced the commercial launch of its Genio system in the Middle East, with the first successful implant performed at Saudi German Hospital in Dubai, UAE. Genio is ...

Nyxoah announces full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA) Mont-Saint-Guibert, Belgium – 26 th January, 2021 – Nyxoah SA (Euronext: NYXH) ...

Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and ...

The Genio system is now available in the US for OSA patients who meet eligibility criteria. The Food and Drug Administration (FDA) has approved the Genio ® system for the treatment of patients with ...

Mont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for ...

(RTTNews) - Nyxoah SA (NYXH), a medical technology company specializing in innovative treatments for Obstructive Sleep Apnea (OSA), announced the successful implantation of its Genio system in the ...

Nyxoah NYXH recently announced that the CY2026 Hospital Outpatient Prospective Payment System (“HOPPS”) and Ambulatory Surgery Center (“ASC”) Rule has been finalized by the U.S. Centers for Medicare & ...

First Genio implants successfully performed at OLVG West and Zuyderland hospitals Mont-Saint-Guibert, Belgium – December 17, 2025, 7:05am CET / 1:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ( ...

Mont-Saint-Guibert, Belgium – August 8, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough ...

Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition ...